USP15 a potential ovarian cancer target

A study in Nature Communications by researchers at Baylor College of Medicine and University of Texas MD Anderson Cancer Center suggests inhibiting ubiquitin specific peptidase 15 could help treat ovarian cancers that carry the R175H mutant of p53.

p53 is one of the most commonly mutated tumor suppressors in cancer patients and is considered an "undruggable" target. Gain-of-function mutations in the p53 gene, including R175H, drive cancer development and drug resistance by altering alternative gene expression and transcriptional activity...